Oscotec Inc. is focused on developing innovative therapies for various serious medical conditions, including non-small cell lung cancer, rheumatoid arthritis, immune thrombocytopenia, acute myeloid leukemia, and Alzheimer's disease. The company has a robust pipeline that highlights its commitment to addressing unmet medical needs through advanced research and development. One of the notable products in their pipeline is OCT-589, which is aimed at treating these complex diseases, showcasing Oscotec's dedication to translating scientific discoveries into effective medical solutions.

The technologies employed by Oscotec are centered around targeted therapies and inhibitors that aim to modulate specific biological pathways involved in disease progression. Their research emphasizes the development of small molecule inhibitors, which are designed to interfere with the activity of particular proteins that contribute to the pathophysiology of the diseases they are targeting. This approach not only aims to improve treatment efficacy but also seeks to minimize side effects, thereby enhancing patient outcomes in the long term.

South Korea

“At Oscotec, our mission is to create values by translating cutting edge science into innovative medicines for clinically unmet needs”

Oscotec

Company Details